Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (USD $) In Thousands, except Share data	Total USD ($)	Series A Preferred Stock USD ($)	Series C Preferred Stock USD ($)	Series B-1 12% redeemable convertible preferred stock USD ($)	Series B-2 12% redeemable convertible preferred stock USD ($)	Series C super dividend convertible preferred stock USD ($)	Series A 12% convertible preferred stock USD ($)	Common Stock USD ($)	Common Stock Series A Preferred Stock	Common Stock Series B One Preferred Stock	Common Stock Series B Two Preferred Stock	Common Stock Series C Preferred Stock	Additional Paid-In Capital USD ($)	Additional Paid-In Capital Series A Preferred Stock USD ($)	Additional Paid-In Capital Series B One Preferred Stock USD ($)	Additional Paid-In Capital Series B Two Preferred Stock USD ($)	Additional Paid-In Capital Series C Preferred Stock USD ($)	Deficit Accumulated During the Development Stage USD ($)	Deficit Accumulated During the Development Stage Series A Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B One Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B Two Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series C Preferred Stock USD ($)
Beginning Balance at Dec. 31, 2011	$ (2,125)			$ 1,681	$ 2,687	$ 2,154	$ 632	$ 13					$ 66,367					$ (69,137)
Beginning Balance (in shares) at Dec. 31, 2011				900,000	2,100,000	220	1,562,500	12,919,538
Accretion of Series B redeemable convertible preferred stock	(130)			13	117													(130)
Accretion of beneficial conversion feature for Series B-2	(42)				42													(42)
Issuance of common stock and warrants, net of issuance costs of $1,597,000 (in shares)								2,666,722
Issuance of common stock and warrants, net of issuance costs of $1,597,000	10,403							3					10,400
Issuance of shares related to reverse split of common stock								3,324
Convertible preferred stock dividend (in shares)									31,250	67,259	156,936	46,053
Convertible preferred stock dividend		47	33											103	166	386	127		(56)	(166)	(386)	(94)
Issuance of common stock to a consultant (in shares)								11,348
Issuance of common stock to a consultant	26												26
Issuance of common stock upon exercise of warrants								12,177
Issuance of common stock upon exercise of options	51,830							51,830
Stock-based compensation expense	2,144												2,144
Net loss	(7,299)																	(7,299)
Ending Balance at Sep. 30, 2012	$ 3,057			$ 1,694	$ 2,846	$ 2,154	$ 632	$ 16					$ 79,719					$ (77,310)
Ending Balance (in shares) at Sep. 30, 2012				900,000	2,100,000	220	1,562,500	15,966,437